Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double-blind, Placebo-controlled, Dose-escalation Study for the Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Oral Doses of GLPG1690 in Healthy Male Subjects

Next Previous
Trial Profile

Randomized, Double-blind, Placebo-controlled, Dose-escalation Study for the Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Oral Doses of GLPG1690 in Healthy Male Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 12 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ziritaxestat (Primary) ; Ziritaxestat (Primary)
  • Indications Idiopathic pulmonary fibrosis; Systemic scleroderma
  • Focus Adverse reactions; First in man
  • Sponsors Galapagos NV; Lakefront Biotherapeutics

Most Recent Events

  • 07 May 2026 According to Galapagos NV media release, Galapagos NV is now called Lakefront Biotherapeutics.
  • 23 Apr 2019 Results assessing the Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects in Phase 1 Randomized Trials, published in the Journal of Clinical Pharmacology
  • 06 Apr 2019 Results evaluating exposure response relationship of GLPG 1690 and further develop a rational basis to support dose selection for clinical trials in patients with idiopathic pulmonary fibrosis published in the Clinical Pharmacokinetics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top